Optimer Pharmaceuticals, Inc. to Present at November 2012 Investor Conferences

JERSEY CITY, N.J., Nov. 7, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the below listed investor conferences in November. The presentations will include an overview of the company and an update on recent business activities.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

• 2012 Credit Suisse Healthcare Conference on Wednesday, November 14 at 1:00 PM Eastern time at The Arizona Biltmore in Phoenix.
• Jefferies 2012 Global Healthcare Conference in London on Thursday, November 15 at 6:20 AM Eastern time at the Waldorf Hilton in London, UK.

Live audio webcasts of the presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com. Replays of the presentations will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR. The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
(619) 849-6005

SOURCE Optimer Pharmaceuticals, Inc.